Clinical Development Pharma Companies Pharmaceuticals 
Drug Target Review
SEPTEMBER 5, 2024
However, my goal was all the time to work with drug development in the pharma industry, so I moved on and started that journey in 1992 when I took on a role as Clinical Research Manager at AstraHässle, a mid-size Swedish pharma company.
The Connected Lab
APRIL 8, 2020
It is reported that every one of the major pharmaceutical companies has announced a partnership with at least one AI-based drug development company, but how is AI being used to facilitate drug development? A Tough Road: Cost To Develop One New Drug Is $2.6 How is AI being applied in Drug Discovery efforts?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JANUARY 4, 2021
Rothenberg did not provide any information as to what his next role may be – whether he will take over the helm of a pharma company or assume a role on one or more boards of directors. Rothenberg took over as Pfizer CMO in January 2019, but spent more than 12 years in total working for the pharmaceutical giant.
Drug Target Review
OCTOBER 1, 2024
Following clinical practice, I transitioned to the world of pharmaceutical companies which also had its challenges as I had to learn everything from scratch and use my experience and knowledge differently. Being a doctor means giving courage and hope day in, day out to those experiencing illness.
Vial
MARCH 1, 2024
Introduction Contract research organizations (CROs) are essential in pharmaceutical research and development (R&D). PPD serves pharma, biotech, medical device, and government entities as a strategic partner in clinical development and analytical services. completed its acquisition of PPD.
The Pharma Data
DECEMBER 17, 2020
Hartfield previously served as CEO of Vitae Pharmaceuticals prior to its acquisition by Allergan. X4 Pharmaceuticals – Diego Cadavid was named chief medical officer of Boston-based X4 Pharmaceuticals. Cadavid will be responsible for the strategy, direction and execution of the company’s clinical development programs.
The Pharma Data
DECEMBER 21, 2020
The FOCUS trial is Ultimovacs’ fourth Phase II clinical trial with UV1 and comes in addition to the collaboration Phase II trial announced in May 2020. “We To date, UV1 has been tested in four phase I clinical trials in a total of 82 patients and maintained a positive safety and tolerability profile as well as encouraging signals of efficacy.
Expert insights. Personalized for you.
111 
Let's personalize your content